Buy Cerebrolysin in Canada: A Researcher’s Guide
Cerebrolysin is not a single peptide but a defined mixture of low-molecular-weight neuropeptides and amino acids, studied for its association with neurotrophic signalling in neuroprotection and cognition research models. It is supplied as a higher-mass vial than most single peptides, and the sourcing questions are the same.
Why researchers source Cerebrolysin domestically
Cross-border orders invite customs delays and seizures. Cerebrolysin (60 mg) ships from within Canada, third-party tested, with e-transfer and credit card accepted, same-day dispatch before 3 PM PST, and free shipping over $150.
What to check before you buy
- Purity documentation on the product page.
- Format, supplied in a sealed vial for laboratory research handling; reconstitution uses eau bactériostatique.
- Research-use framing, sold for research only; see our legal overview.
Where it fits
Cerebrolysin sits within cognitive and nootropic research alongside Semax and Selank. The wider set is on the Recherche cognitive et nootropique page.
Frequently asked questions
Where can I buy Cerebrolysin in Canada?
From domestic research suppliers. Vistara Labs stocks Cerebrolysin 60 mg and ships from within Canada.
Is Cerebrolysin a single peptide?
No. It is a defined mixture of low-molecular-weight neuropeptides and amino acids.
Is Cerebrolysin legal in Canada?
It is sold for laboratory research use only. It is not sold for human use, and nothing here is medical advice.
All products discussed are for laboratory research use only and are not for human use. Nothing on this page is medical advice, and no statement about any compound is a claim of therapeutic or cosmetic benefit.
References
Cerebrolysin has substantial human neurological research, with results that vary by condition, outcome measure and study design.
- Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trialRandomised, double-blind, placebo-controlled multicentre trial; 242 patients with vascular dementia, 24 weeks.
- Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agentRandomised, double-blind, placebo-controlled trial; 192 patients with Alzheimer's disease.
- Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized studyRandomised, double-blind, placebo-controlled pilot; 32 patients with mild traumatic brain injury.
- Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis of 7 randomised trials, 1,779 acute ischaemic stroke patients; no significant superiority on major functional outcomes.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
